Healthcare Industry News: Rebif
News Release - June 14, 2012
EMD Serono, Inc. Strengthens Leadership Teams with New AppointmentsAllene Diaz, Senior Vice President, Head of US Oncology
Evan Lippman, Senior Vice President of Neurodegenerative Diseases and Rheumatology
Rami Levin, Vice President of Marketing, Neurodegenerative Diseases and Rheumatology
Craig Millian, Senior Vice President, Head of US Fertility, Metabolic Endocrinology and HIV
ROCKLAND, Mass.--(Healthcare Sales & Marketing Network)--EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today the appointments of Allene Diaz, Senior Vice President, Head of US Oncology; Evan Lippman, Senior Vice President of Neurodegenerative Diseases and Rheumatology; Rami Levin, Vice President of Marketing, Neurodegenerative Diseases and Rheumatology; and Craig Millian, Senior Vice President, Head of US Fertility, Metabolic Endocrinology and HIV.
Allene Diaz brings more than 25 years of both US-based and international industry experience to the newly created role of Senior Vice President, Head of US Oncology. She will be responsible for leading the commercial efforts for EMD Serono’s US Oncology business. Since 2008, Ms. Diaz has worked diligently to strengthen the oncology presence of EMD Serono in the US. From July 2010 through April 2011, she also served as Acting Head, Global Strategic Planning, defining and leading the 2011 strategic planning process for Merck Serono’s Oncology Business Unit.
Prior to joining EMD Serono, Ms. Diaz served in senior leadership roles in marketing, new product planning and portfolio management at Amylin Pharmaceuticals, CancerVax Corporation, Biogen Idec and Pfizer. She began her professional career with Parke-Davis Pharmaceuticals as a sales representative. She received a BS from Florida State University.
Evan Lippman joins EMD Serono as Senior Vice President of the Neurodegenerative Diseases and Rheumatology Franchise. He comes from AstraZeneca, where he most recently served as Executive Director of the company’s multi-billion dollar Crestor® (rosuvastatin calcium) brand, following a number of leadership roles, including Executive Director and Head of US Business Development.
Prior to AstraZeneca, Mr. Lippman held positions of increasing responsibility at Pfizer. He began his career in corporate finance and investment banking with such companies as Bank of America, Kurt Salmon Associates, Schroder & Co., Cohen & Steers Capital Advisors and the Bear Stearns Companies. He received a BA in Political Science from Bucknell University, a BA in Business from Georgia State University and an MBA from Cornell University.
Reporting to Mr. Lippman will be Rami Levin, who has been appointed Vice President of Marketing, Neurodegenerative Diseases and Rheumatology. Mr. Levin has been with Merck Serono since 1998, most recently as Chairman and Managing Director of Merck AB in Sweden and Iceland. Prior to that, he served as Global Marketing Director for Neurology at Merck Serono, Geneva, and as the Global Product Manager for Rebif.
Mr. Levin began his career as a Business Unit Manager in Neurology at Serono Israel. Before joining Merck Serono, he worked at Schering AG Israel as both a Product Manager and Sales Representative for the company’s Neurology Team. Mr. Levin received a BS in Biology from Tel Aviv University and an MBA from Recanati Business School at Tel Aviv University.
Craig Millian joins as Senior Vice President and Head of EMD Serono’s US Fertility, Metabolic Endocrinology and HIV franchise after taking over this role on an ad-interim basis earlier this year. Prior to his new role, he led the marketing organization supporting brands across reproductive health, growth hormone deficiency and HIV-related metabolic disorders as Vice President of Endocrinology Marketing.
Mr. Millian previously served as Vice President, Commercial at Vertex Pharmaceuticals, held several marketing leadership roles at Pfizer Inc. and worked in roles of increasing responsibility within Marketing and Managed Care at Sanofi US. He received a BS in Finance from the University of Pennsylvania and an MBA from New York University.
Ms. Diaz, Mr. Lippman and Mr. Millian will serve as members of EMD Serono’s Executive Committee.
About EMD Serono, Inc.
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, endocrinology and in reproductive health. In addition, EMD Serono is growing its expertise and presence in the area of oncology, with more than 15 projects currently in development. With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono’s US footprint continues to grow, with approximately 1,000 employees around the country and fully integrated commercial, clinical and research operations in the company’s home state of Massachusetts.
For more information, please visit www.emdserono.com.
About Merck KGaA
Merck is a global pharmaceutical and chemical company with total revenues of € 10.3 billion in 2011, a history that began in 1668, and a future shaped by more than 40,000 employees in 67 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
For more information, please visit www.merckserono.com or www.merckgroup.com.
Source: EMD Serono
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.